Skip to main content

Diabetes Mellitus: Pharmacotherapy- Glinides and Biguanides!

 PHARMACOTHERAPY

2.NONSULFONYLUREA SECRETAGOGUES (GLINIDES)

  • Although producing the same effects as sulfonyl ureas, Non sulfonylurea secretogogues also referred to as Glinides or Meglitinides have rapid onset and short duration of action.

Mechanism of Action:

  • Glinides produce a pharmacological action by interacting with ATP-Sensitive potassium channels on the beta cells; however, this binding is to a receptor adjacent to those with which the sulfonyl ureas bind.

Clinical Uses:

  • The primary benefit is in reducing post-meal glucose levels.
  • These agents have resulted in a reduction of 0.8-1% A1c levels.

Indications:

  • Because they have a rapid onset of action, Glinides are supposed to be taken 15-30 minutes before the meal.

Therapy:

  • They may also be used in combination therapy with other drugs to achieve synergistic effects.
  • Combinations with Biguanides is mostly used.


3.BIGUANIDES

  • Biguanides include Metformin as the Drug of choice for T 2 DM.

Mechanism of Actions:

  • Biguanides are thought to lower the blood glucose levels by decreasing hepatic glucose production and increasing insulin sensitivity in both hepatic and peripheral muscle tissues; however, the exact mechanism of action is unknown. 

Clinical uses:

  • Metformin reduces both Fasting Blood Glucose levels and post-meal glucose levels.
  • It has shown to reduce A1c levels by 1.5-2% and FPG levels by 60-80mg/dL when used as a monotherapy.
  • Unlike sulfonylureas, metformin retains the ability to reduce fasting blood glucose levels when they are used over 300mg/dL.
  • Metformin does not affect insulin release from beta cells of the pancreas, so hypoglycemia is not a common side effect.
  • Metformin significantly reduces all-cause mortality and the risk of strokes in overweight patients with T2DM compared to the insensitivity therapy with sulfonylurea or Insulin.
  • It also reduces Diabetes-related death and Myocardial infarction as compared with a conventional Arm therapy.
  • ADA treatment algorithm considers Lifestyle modification and Metformin therapy as the first line therapy for T 2 DM 
  • Metformin has shown to produce beneficial effects on serum lipid levels and has become first-line agents for T2 DM patients with metabolic syndrome.
  • On average, Triglyceride levels and LDL levels may be reduced by as much as 18.69%-12.09% respectively and HDL levels may improve by as much as 1.17%.

Therapy:

  • Metformin is often used in combination with sulfonyl urea or Thiazolidinedione (TZD) for synergistic effects.

Pharmacokinetics:

  • Metformin does not undergo significant protein binding and is eliminated from the body via urine unchanged.

Contraindications:

  • Metformin is contraindicated in patients with:

  1. patients having creatinine clearance less than 60mL/min.
  2. Patients with serum creatinine levels > than or = to 1.4mg/dL in women and 1.5mg/dL in men.
  3. It should not be initiated in patients of 80 years of age or older unless renal function has been established.
  4. Patients undergoing radiographic procedures in which nephrotoxic dye is used.
  5. Biguanides inhibit mitochondrial oxidation of lactic acid, thereby increasing the chances of lactic acidosis occurring..
  6. Metformin should be withheld in pt. with cases of hypoxemia, sepsis or dehydration.
  7. Patients should avoid consumption of excessive alcohol with Metformin intake.

Adverse Drug Reactions:

  • Primary side effects include:

                         GIT upset, Decreased appetite, Nausea, Diarrhea

  • Interference with Vitamin B12 absorption is also reported.


Labels:

Comments

Post a Comment

Popular posts from this blog

General Mechanism of Actions of INSULIN.

GENERAL MECHANISM OF ACTION OF INSULIN AND RELATE HORMONES The body's main fuel is Glucose. Glucose is stored in the liver and muscles as Glycogen.  Excess glucose is stored in the adipose tissues which yield fatty acids via lipolysis. In the fasting state, free fatty acids supply much of the energy needs of the body except for the CNS which requires Glucose to function normally. Proteins can also be converted to glucose via gluconeogenesis. RELEASE OF INSULIN AND GLUCAGON Insulin and Glucagon are produced in the pancreas by the Islets of Langerhans . Beta cells   make up 70%-90% of the Islets and produce Insulin and Amylin while the a-cells   produce glucagon. The main function of insulin is to decrease blood glucose levels. Glucagon, along with other counter-regulatory hormones such as growth factor, cortisol, and Epinephrine, increases Blood glucose levels.  The opposing actions of Glucagon and Insulin along with other counter-regulatory hormones maintain a norma...
Post a Comment
Read more

Diabetes Mellitus: Its Goals Of Therapy!

  GOAL OF THERPY The goals of treatment of DM includes; Reducing, controlling and managing long-term microvascular, macrovascular and neuropaathic complications. Preserving beta cell function. Preventing acute complications from increased Blood glucosel level. Minimizing hypoglycemic episodes. Maintaining patient quality of life. --Two landmark trials, THE DIABETES CONTROL AND COMPLICATION TRIAL (DCCT) and THE UNITED KINGDOM PROSPECTIVE DIABETES STUDY(UKPDS), showed that lowering blood glucose levels decreased the risk of developing chronic complications. --A near normal blood glucose level can be achieved with appropriate patient education , lifestyle modification and medications . --Proper care of DM requires goal setting and assessment for glycemic control , self-monitoring of blood glucose (SMBG) monitoring of blood glucose pressure , and lipid levels , regular monitoring for the development of complications , dietary and exercise lifestyle modifications and proper medicatio...
Post a Comment
Read more

Diabetes Mellitus: Clinical Presentation and Diagnosis!

 CLINICAL PRESENTATION AND DIAGNOSIS OF DM 2. SCREENING American Diabetes Association (ADA) recommends routine screening for T2 DM every 3 years in all adults starting at 45 years of age. Testing of T2 DM should be considered in any adult, regardless of their age, who have a BMI greater than or equal to 25kg/m2. The ADA does not currently recommend widespread screening for T1 DM because of the relatively low incidence in the general population, although measurement of Islet antibodies may be appropriate for high-risk individuals. 3.GESTATIONAL DIABETES: "Gestational diabetes is the glucose intolerance in women during pregnancy". All pregnant women who have risk factors for T2 DM should be screened for undiagnosed T2 DM at their first prenatal visit using standard diagnostic criteria.  Any women found to have diabetes in the early point at pregnancy is considered to have T2 DM or GDM. All other pregnant women, not currently known to have DM should be screened for GDM with a 75...
Post a Comment
Read more